Find information on thousands of medical conditions and prescription drugs.

Aricept

Donepezil, marketed under the trade name AriceptĀ® (Eisai), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. It is well absorbed in the gut with an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The clinical utility of donepezil is controversial. Presently, there is no proof that use of donepezil or other similar agents alters the course or progression of Alzheimer's disease. However, controlled studies have shown modest benefits in cognition and behavior with this and similar agents. Therefore, many neurologists, psychiatrists, and primary care physicians use donepezil in patients with Alzheimer's disease. As of the 22 March 2005, the UK National Institute for Clinical Excellence (NICE) withdrew its recommendation for use of the drug for mild-to-moderate AD, on the basis that there is no significant improvement in functional outcome; of quality of life or of behavioral symptoms. However, these data conflict with those of other reports, as is often the case in medicine.

Donepezil is sometimes used in combination with Memantine, a new agent for Alzheimer's disease which is in the same chemical class. The response to both together is superior to either alone.

Donepezil has been tested in other disorders which cause dementia including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications.

Sources

  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4

Read more at Wikipedia.org


[List your site here Free!]


The math of healthcare
From Health Management Technology, 9/1/05 by Robin Blair

One night in late June, I sat down to read U.S. News & World Report, expecting to read half the issue. Instead, I read one article four times.

My paternal grandmother died more than three decades ago. She had Alzheimer's. Although we know more about it today, and it has become pharmaceutically treatable in early stages, the disease remains unpreventable and incurable. Many of us with aging parents have an up-close-and-personal relationship with dementia-related diseases. Some of us speculate on whether we are tomorrow's victims. Some of us will be.

The article described the Mini Mental State Examination, a commonly used, no-tech memory test that physicians administer to patients to begin assessment for Alzheimer's. The problem is that the test takes 10 minutes. That exceeds the length of the average PCP appointment by two to four minutes, so most physicians are unlikely to administer it. The answer, proclaimed this article, is that researchers have developed three other, equally no-tech test vehicles that take but five minutes or less to administer.

Estimates are that approximately 3 million victims of Alzheimer's cost the U.S. about $50 billion annually to treat and care for, averaging out at $16,667 per person per year. All of those researchable metrics seem to be lowball estimates by my personal calculations and are the tip of the iceberg.

A 2003 MetLife data analysis puts the U.S. baby boomer population at 77,702,865. By 2030, boomers will be ages 66 to 84 and will constitute 20 percent of the U.S. population. If even 5 percent of them are dementia candidates, that's 3,885,143 people who will be afflicted, some beginning tomorrow and many within 10 years.

Legislators in Washington are posturing to put $4 billion on the table so providers can buy, lease, upgrade and implement IT systems. It sounds like a lot. We do our victory dance and publicly herald healthcare IT as an idea whose time finally has arrived at the funding table. If another $4 billion were used to pay for a 10-minute dementia test for 3,885,143 people, the cost would be about $1,000 per person per test. At today's prices, that would provide a dementia patient with considerably less than a year's supply of Aricept.

I'm a huge proponent of EHRs, of funded mandates and of nationwide IT integration, although it takes but a few depressing statistics to dislodge me from my soapbox. I can have diagnostic images of my knee taken here in Florida, sent to a nighthawk radiologist in India and have his diagnosis back to my physician in 24 hours. You can have implanted into your arm a chip containing a sizable chunk of personal health information. Legislators can volley to loosen $4 billion from government coffers so providers can buy, lease and upgrade IT systems to participate in a nationwide network of electronic interoperability. But 3.8 million baby boomers can't receive a 10-minute memory test from their PCPs because 10 minutes is longer than the average doctor's appointment. They can remain at risk for losing two, five, 10 or more years of their lives to a hideous disease, for the sake of five minutes of physicians' time.

What's wrong with this picture? Perhaps we have designed a cart, skipped entirely over the horse and are trying to hitch it directly to a jet engine.

COPYRIGHT 2005 Nelson Publishing
COPYRIGHT 2005 Gale Group

Return to Aricept
Home Contact Resources Exchange Links ebay